$ cat ./records/gates-foundation-commits-107-6-million-to-rts-s-malaria-vaccine-w-2005.txt
Gates Foundation Commits $107.6 Million to RTS,S Malaria Vaccine with GSK
[RECORD.TXT] · cat --full
The Gates Foundation awarded $107.6 million to PATH's Malaria Vaccine Initiative to advance RTS,S — the malaria vaccine candidate developed with GlaxoSmithKline — through large-scale Phase III clinical trials across African research centres. Gates ultimately contributed more than $200 million to the project. In 2021 the WHO endorsed RTS,S as the world's first malaria vaccine, and by 2023 over 2 million children in sub-Saharan Africa had received at least one dose, marking one of public health's most sought-after milestones.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Foundation Commits $75 Million to Target Malaria CRISPR Gene Drive Research Program
Next →
Called for complete removal of H-1B visa caps, stating 'I don't think there should be any limit'
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.